Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

TargeGen

2002 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$560M LATEST DEAL AMOUNT
Description

Developer of small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 9380 Judicial Drive
  • San Diego, CA 92121
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore TargeGen’s full profile, request a free trial.

TargeGen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Jul-2010 $560M 00000 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 12-Jul-2007 000.00 00000 00000 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 31-Aug-2005 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 13-Jan-2004 $30.6M $40.6M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 03-Apr-2002 $10M $10M 0000 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

TargeGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 000
Series B 27,061,947 $0.000100 $0.09 $1.13 $1.13 1x $1.13 22.55%
Series A 10,000,000 $0.000100 $0.08 $1 $1 1x $1 8.33%
To view this company’s complete Cap Table, request access »

TargeGen Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BB Biotech Ventures Venture Capital Minority 000 0000 000000 0
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Chicago Growth Partners PE/Buyout Minority 000 0000 000000 0
Enterprise Partners Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »